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Stem cells are emerging as therapeutic candidates in a variety of diseases because 
of their multipotent capacities. Among these, mesenchymal stem cells (MSCs) de-
rived from bone marrow, umbilical cord blood or adipose tissue, comprise a popu-
lation of cells that exhibit extensive proliferative potential and retain the ability to 
differentiate into multiple tissue-specific lineage cells including osteoblasts, chon-
drocytes, and adipocytes. MSCs have also been shown to enhance neurological re-
covery, although the therapeutic effects seem to be derived from an indirect para-
crine effect rather than direct cell replacement. MSCs secrete neurotrophic factors, 
promote endogenous neurogenesis and angiogenesis, encourage synaptic connec-
tion and remyelination of damaged axons, decrease apoptosis, and regulate inflam-
mation primarily through paracrine actions. Accordingly, MSCs may prevail as a 
promising cell source for cell-based therapy in neurological diseases.
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INTRODUCTION
Stem cells are emerging as therapeutic candidates in a variety of disease because 
of their multipotent capacities. Embryonic stem cells are pluripotent and can dif-
ferentiate into all specialized cell types derived from the three embryonic germ 
layers. Nevertheless, both ethical and technical considerations limit the clinical 
availability of these cells. Other potential cell sources, especially for central ner-
vous system (CNS) repair, include fetal neural stem cells (NSCs) and neural pre-
cursor cells (NPCs). NSCs can be expanded over multiple passages and do not re-
quire the recapitulation of early developmental signals to induce neuroectodermal 
commitment, as they are already neuralized and committed to a CNS cell fate.1 
However, transplantation of fetal NSCs into the adult brain encompasses numer-
ous ethical and scientific hurdles.1-3 Because of their plastic ability to survive as 
undifferentiated cells in ectopic perivascular niches,4 NPCs have been tested in an-
imal models of neurological diseases. These cells also release paracrine factors 
that foster survival and proliferation of endogenous neural progenitor cells. How-
ever, the application of terminal differentiation of NPCs into neural-lineage cells to 
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ocytes and skeletal muscle,23 although there is a lack of 
definitive evidence as to the functionality of these differen-
tiated cells.26,27 Nevertheless, MSCs have considerably con-
tributed to tissue repair in myocardial infarction (MI),28 
stroke,29,30 meniscus injury,31 and limb ischemia.32 
In this review, we will discuss the therapeutic mecha-
nisms of MSCs for neurorestoration and neural regenera-
tion. Thereafter, we will review the published reports of 
clinical trials for a variety of neurological diseases includ-
ing stroke, traumatic brain injury, spinal cord injury, Parkin-
son’s disease (PD), amyotrophic lateral sclerosis (ALS), 
and multiple sclerosis (MS).
THERAPEUTIC MECHANISMS OF  
MSCS FOR NEURORESTORATION
Secretion of neurotrophic factors
MSCs secrete a variety of cytokines and growth factors that 
promote endogenous neuronal growth, neurogenesis and 
angiogenesis, encourage synaptic connection and remyelin-
ation of damaged axons, decrease apoptosis, and regulate 
inflammation primarily through paracrine actions (Fig. 1). 
replace damaged cells remains controversial.5
In contrast, adult stem cells, responsible for maintaining 
the homeostasis of a specific tissue with fewer ethical prob-
lems. One of the most extensively studied populations of 
multipotent adult stem cells is mesenchymal stem cells 
(MSCs), which are derived from bone marrow (BM). They 
can also be isolated from other tissues such as umbilical 
cord blood,6 synovium,7 periosteum,8 peripheral blood,9 adi-
pose tissue,10 skeletal muscle,11 and placental tissue.12 MSCs 
are an excellent candidate for cell therapy because they are 
easily accessible; can be easily isolated and expanded rapid-
ly in vitro;13 are multipotent;14,15 involve minimal loss of po-
tency;16,17 form supportive stroma for hematopoiesis and 
support stem cell engraftment;18 may not require immune 
suppression;19,20 seem to be largely immunologically inert, 
paving the way for allogeneic transplantation;21 secrete nu-
merous trophic factors that modulate inflammation and 
apoptosis.22 The large body of work that has accumulated 
since the discovery of human MSCs has convincingly 
shown that MSCs from diverse sources retain the ability to 
differentiate into the mesodermal lineage cells including os-
teoblasts, chondrocytes and adipocytes.23,24 They also ex-
hibit the ability to differentiate into neurons-like cells,25 my-
Fig. 1. Potential therapeutic mechanisms of neurorestoration using mesenchymal stem cells. MSCs secrete a variety of neurotrophic fac-
tors that promote endogenous neuronal growth, induce angiogenesis, neurogenesis and astroglial activation, encourage synaptic con-
nection and axonal remyelination, decrease apoptosis, and regulate microglial activation primarily through paracrine actions. MSCs, 
mesenchymal stem cells.
Synaptic connection
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Neurotrophic factors
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Apoptosis
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able functional recovery obtained with the administration 
of MSCs in experimental models of stroke as well as spinal 
cord injury.43,44
 
Immunomodulatory effect
MSCs were shown to exert immunomodulatory properties 
in vitro.45 These features were exploited by researchers in 
the treatment models of MS and experimental autoimmune 
encephalomyelitis.46,47 In PD, MSCs act as neuroprotectors 
via an anti-inflammatory response to regulate the activity of 
microglia and to protect dopaminergic neurons.48,49 In isch-
emic brain, MSCs were also useful as an immunomodula-
tor.50 MSCs reduced the numbers of Iba-1+ and ED1+ in-
flammatory cells.39 In our previous study, intravenously 
transplanted MSCs did not only decrease the level of pro-in-
flammatory cytokine IL-1β and the proportion of activated 
microglia, but also increased the level of anti-inflammatory 
cytokine IL-10, potentially suggesting that early immuno-
modulation by MSCs was an underlying mechanism of 
functional recovery in spinal cord injured rats.51
Induction of angiogenesis 
MSCs secrete a number of growth factors and cytokines, 
which normally support the proliferation of hematopoietic 
stem/progenitor cells.22 In experimental models of cardio-
vascular diseases such as MI and limb ischemia, the secre-
tion of multiple angiogenic cytokines such as hepatocyte 
growth factor, basic fibroblast growth factor, insulin-like 
growth factor 1 and vascular endothelial growth factor was 
induced from MSCs.52-56 Existing evidence suggests that 
these cells can ameliorate ischemic tissue injury, produce 
appropriate cytokine milieu to promote angiogenesis, and 
possibly differentiate into endothelial cells.54,55,57 The evi-
dence seems to point toward the theory that a complex set 
of trophic factors secreted by MSCs significantly contrib-
utes to injury repair in vivo by stimulating angiogenesis.
Host cell effects stimulated by MSC transplantation
MSCs are believed to secrete neurotrophic factors, immuno-
modulatory cytokines, pro-angiogenic factors, extracellular 
matrix molecules and so on. Thus, the therapeutic effects of 
transplanted MSCs seem to be derived from paracrine ef-
fects rather than direct cell replacement. It is conceivable 
that MSCs or host brain cells stimulated by grafts may pro-
duce such proteins to induce functional recovery and reorga-
nization.58 MSC-induced secretion of beneficial cytokines 
by host cells in subjects with neurological diseases such as 
Human MSCs are known to secrete neurotrophic factors in-
cluding brain-derived neurotrophic factor (BDNF), ciliary 
neurotrophic factor, glial cell line-derived neurotrophic fac-
tor (GDNF), and nerve growth factor (NGF). After direct 
transplantation in an animal model of stroke, human MSCs 
were shown to integrate into host brain, survive, differenti-
ate into neurons and astrocytes, and induce neurobehavioral 
improvement.33 BM-derived MSCs can secrete various tro-
phic factors, the secretion of which is enhanced under post-
ischemic conditions.34,35 In our previous study using a rat 
model of spinal cord injury, neurally induced cells derived 
from umbilical cord blood also exhibited better functional 
recovery in vivo and secreted more NGFs in vitro.36
Induction of neurogenesis and astroglial activation
MSCs induce the proliferation of endogenous neural stem/
progenitor cells in the subventricular zone (SVZ) and are 
critical to the survival of newborn cells.37 They have been 
shown to be directly involved in neural differentiation after 
engraftment into damaged tissue and migrate to the CNS to 
a limited extent.38 Of particular note, genetically modified 
MSCs expressing Neurogenin1, a proneuronal gene that di-
rects neural differentiation, increased the therapeutic effects 
of MSCs in ischemic brain.39 In addition, MSCs promote 
the plasticity of damaged neurons and activate astroglial 
cells to secrete neurotrophins such as BDNF, GDNF and 
NGF.34 In an animal model of stroke, intravenous transplan-
tation of BM stromal cells improved functional outcomes 
by promoting endogenous repair.29
Axonal sprouting and synaptic connection
Previous study suggested that extracellular matrix compo-
nents derived from MSCs can enhance nervous system re-
pair.40 For example, fibronectin prominently performs es-
sential roles in neuronal survival, axonal sprouting and 
synaptogenesis following cerebral ischemia.41 Moreover, 
extracellular matrix molecules and cell adhesion molecules 
such as integrin, cadherin, and selectin can promote axonal 
growth and regeneration.42
Anti-apoptotic effect
Reportedly intravenous transplantation of MSCs reduced 
apoptotic cells stained with terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick-end labeling in an animal model 
of middle cerebral artery occlusion.29 This anti-apoptotic ef-
fect, together with the previously described capacity to re-
lease neurotrophic molecules, may well explain the remark-
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1 year, and trends towards increased functional recovery.71 
This group also reported as a long-term follow-up study for 
5 years no serious adverse effects following MSC treat-
ment.72 Direct administration of MSCs to an injured region 
following traumatic brain injury has also been performed 
without adverse events. Briefly, seven patients each re-
ceived up to 109 expanded MSCs as part of a cranial repair 
operation. The patients were followed up for six months 
and demonstrated significant improvements in neurological 
function.73,74
MSC in spinal cord injury
Depending on the severity and location of injury, patients 
present with a varying range of functional impairments, aris-
ing from both damage to the local circuitry of the spinal 
cord and disruption of the ascending and descending fiber 
tracts.75,76 All groups who have tested the safety of the trans-
plantation of BM-derived mononuclear cells and stromal 
cells, or adipose tissue-derived MSCs in patients with spinal 
cord injury indicate that administration of these cells does 
not cause any serious adverse effects.77-80 Geffner, et al.77 in-
vestigated the improvement in quality of life and bladder 
function without pain or tumor up to 2 years. Syková, et al.78 
reported that five patients who received cells intra-arterially 
showed improvement up to 1 year.
MSC in parkinson’s disease
PD is a progressive neurodegenerative disease whose dopa-
minergic neurons selectively degenerate in the substantia 
nigra. Although a variety of drugs such as L-dopa are avail-
able, they only remain effective for a certain period in most 
patients. The limitation of pharmacologic agents increases 
the need for cell-based therapy as a restorative strategy. In a 
study recently reported by Li, et al.,81 two subjects with PD 
who underwent transplantation of fetal mesencephalic do-
paminergic neurons, which had survived for over 10 years, 
but later developed α-synuclein-positive Lewy bodies in the 
engrafted donor neurons, suggesting that the disease can 
propagate from host to graft cells. On the other hand, when 
autologous BM-derived MSCs were transplanted into the 
SVZ by stereotaxic surgery, the results suggested the treat-
ment to be safe, and no serious adverse events occurred af-
ter transplantation in PD.82 Additionally, when patients with 
multiple system atrophy (MSA) were treated with MSCs, 
greater improvement was noted on the unified MSA rating 
scale than in untreated control patients, and no delayed ad-
verse effects related to MSC infusion occurred during the 
stroke29 as well as spinal cord injury33,44,59 would be a more 
plausible mechanism given that activation of recipient host 
cells after cell transplantation has been previously described 
in other disease models such as MI and ischemic vascular 
disease.60,61
CLINICAL TRIALS IN  
NEUROLOGICAL DISEASES
Several clinical reports on MSC-based treatments have been 
published in the past decade, and evoked great excitement 
for therapeutic candidates for several diseases.62 As early as 
the 1990s, cultured MSCs have already been supplemented 
to reduce acute and chronic graft-versus-host disease among 
patients receiving allogenic hematopoietic stem cell trans-
plantation, as well as to ameliorate clinical symptoms in os-
teogenesis imperfecta and glycogen storage disease.62-64 
Currently, the effective therapeutic benefits of MSCs have 
been supported by increasing numbers of clinical trials on 
various disorders such as MI, cancer, diabetes mellitus, and 
Crohn’s disease.65-68
We will discuss the role of MSCs in neurological diseas-
es, spanning the clinical trials on stroke, spinal cord injury, 
PD, ALS, and MS. A summary of the cell source, route of 
delivery, number of patients, study design, dose of trans-
plant, outcome measures and main results for each thera-
peutic application of MSCs is provided in Table 1.
MSC in stroke and traumatic brain injury 
Neuronal and astroglial damages can occur in cerebrovas-
cular disease resulting from the blockage of blood flow in 
selected brain areas, leading to motor, sensory and cogni-
tive dysfunctions.3 It has been shown that stroke-induced 
endogenous neurogenesis and migration of neural stem or 
progenitor cells into regions of ischemic damage occurs in 
humans, but the extent to which neurogenesis is able to re-
place lost neurons or contributes to functional improvement 
in stroke patients is largely limited.3,69,70 The limited thera-
peutic efficacy of endogenous repair processes has encour-
aged clinicians to incorporate MSCs or BM-derived cells in 
restorative strategies.
Clinical trials for MSC transplantation to treat stroke and 
traumatic brain injury are currently ongoing. In patients 
with middle cerebral artery infarction, the use of autologous 
MSCs derived from BM has indicated no safety concerns 
for death, stroke recurrence, or serious adverse events up to 
MSCs Induce Neurorestoration
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